The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
Open accessAbstract
The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the treatment of colorectal cancer. In this study, we investigate the molecular mechanisms of action of oxaliplatin to identify means of predicting response to this agent. Exposure of colon cancer cells to oxaliplatin resulted in G2/M arrest and apoptosis. Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol. Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association. Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin. However, the mutational status of p53 was unable to predict response to oxaliplatin in a panel of 30 different colorectal cancer cell lines. In contrast, the expression profile of these 30 cell lines, assessed using a 9216-sequence cDNA microarray, successfully predicted the apoptotic response to oxaliplatin. A leave-one-out cross-validation approach was used to demonstrate a significant correlation between experimentally observed and expression profile predicted apoptosis in response to clinically achievable doses of oxaliplatin (R=0.53; P=0.002). In addition, these microarray experiments identified several genes involved in control of apoptosis and DNA damage repair that were significantly correlated with response to oxaliplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289 · cited 1×
“…Bcl-2 family members such as Bax, which normally reside in the cytosol, are relocated to the outer mitochondrial membrane where they lead to the release of apoptotic factors from the mitochondria and ultimately to caspase activation and an apoptotic cell death (Li et al, 1997; Zou et al, 1997).”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c
Liu, X., Kim, C. N., Yang, J., Jemmerson, R., & Wang, X. (1996) · Cell · doi:10.1016/s0092-8674(00)80085-9 · Cited by 5,167
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 1×
“The tumour suppressor gene p53 has been shown to directly regulate the expression levels of Bax (Miyashita and Reed, 1995), and both p53 and Bax have been shown to be important determinants of the cellular response to chemotherapeutic agents (Bunz et al, 1999; Zhang et al, 2000).”
Backgroundde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“…to 5FU, and can also be used in combination with 5FU or CPT-11, improving response rates and progression-free survival (Levi et al, 1993; Bertheault-Cvitkovic et al, 1996; Machover et al, 1996; de Gramont et al, 1997, 2000; Andre et al, 1999; Maindrault-Goebel et al, 1999; Giacchetti et al, 2000).”
BackgroundBCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Zou, H., Henzel, W. J., Liu, X., Lutschg, A., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80501-2 · Cited by 3,145
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mitochondria as the central control point of apoptosis
Desagher, S., & Martinou, J.-C. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01803-1 · Cited by 1,913
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
A novel form of Epstein-Barr virus latency in normal B cells in vivo
Miyashita, E. M., Yang, B., Lam, K. M. C., Crawford, D. H., & Thorley-Lawson, D. A. (1995) · Cell · doi:10.1016/0092-8674(95)90513-8 · Cited by 1,593
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,063
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 11×
“The platinum compound oxaliplatin is frequently used in the treatment of colorectal cancer patients that are resistant to 5FU, and can also be used in combination with 5FU or CPT-11, improving response rates and progression-free survival (Levi et al, 1993; Bertheault-Cvitkovic et al, 1996; Machover et al, 1996; de Gra…”
BackgroundInfluentialNarita, M., Shimizu, S., Ito, T., Chittenden, T., Lutz, R. J., Matsuda, H., & Tsujimoto, Y. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14681 · Cited by 933
Role of BAX in the Apoptotic Response to Anticancer Agents
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., & Vogelstein, B. (2000) · Science · doi:10.1126/science.290.5493.989 · Cited by 863 · cited 3×
“Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells D Arango*,1,2, AJ Wilson1, Q Shi3, GA Corner1, MJ Arañes1, C Nicholas1, M Lesser4, JM Mariadason1 and LH Augenlicht1 1Oncology Department, Albert Einstein Cancer Center, Montef iore Medical Center,…”
BackgroundMethodSalonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., André, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., & Krulik, M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00370-x · Cited by 386
Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V, Izrael, V, Krulik, M., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00149-5 · Cited by 290
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
André, T., Bensmaine, M. A., Louvet, C., François, E., Lucas, V., Desseigne, F., Beerblock, K., Bouché, O., Carola, E., Merrouche, Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3560 · Cited by 277
Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Itzhaki, M., Iacobelli, S., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90073-o · Cited by 218
Aven, a Novel Inhibitor of Caspase Activation, Binds Bcl-xL and Apaf-1
CHAU, B. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00005-8 · Cited by 213
Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A., Chambaz, J., Lacorte, J., Staedel, C., & Lesuffleur, T. (2002) · International Journal of Cancer · doi:10.1002/ijc.10146 · Cited by 213
Mariadason, J. M., Arango, D., Shi, Q., Wilson, A. J., Corner, G. A., Nicholas, C., Aranes, M., LESSER, M. L., Schwartz, E. L., & Augenlicht, L. H. (2003) · PubMed · Cited by 210
Self-citationZembutsu, H., Ohnishi, Y., Tsunoda, T., Furukawa, Y., Katagiri, T., Ueyama, Y., Tamaoki, N., Nomura, T., Kitahara, O., Yanagawa, R., et al. (2002) · PubMed · Cited by 201
Kihara, C., Tsunoda, T., Tanaka, T., Yamana, H., Furukawa, Y., Ono, K., Kitahara, O., Zembutsu, H., Yanagawa, R., Hirata, K., et al. (2001) · PubMed · Cited by 198
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
Arnould, S., Hennebelle, I., Canal, P., Bugat, R., & Guichard, S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00411-2 · Cited by 168
Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 status
Magrini, R., Bhonde, M., Hanski, M., Notter, M., Scherübl, H., Boland, C. R., Zeitz, M., & HANSKI, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10565 · Cited by 121
Pharmacokinetics of Oxaliplatin in Humans
Ehrsson, H., Wallin, I., & Yachnin, J. (2002) · Medical Oncology · doi:10.1385/mo:19:4:261 · Cited by 120
Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis.
Deacon, E. M., Pongracz, J. E., Griffiths, G., & Lord, J. M. (1997) · Molecular Pathology · doi:10.1136/mp.50.3.124 · Cited by 111
Arango, D., Corner, G. A., Wadler, S., Catalano, P. J., & Augenlicht, L. H. (2001) · PubMed · Cited by 109
Self-citationHayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., & Jodrell, D. I. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.169.3.2 · Cited by 102
Gourdier, I., Rio, M. D., Crabbé, L., Candeil, L., Copois, V., Ychou, M., Auffray, C., Martineau, P., Mechti, N., Pommier, Y. G., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03347-1 · Cited by 97
c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis
Arango, D., Mariadason, J. M., Wilson, A. J., Yang, W., Corner, G. A., Nicholas, C., Aranes, M., & Augenlicht, L. H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601338 · Cited by 93
Self-citationRakitina, T. V., Vasilevskaya, I. A., & O'Dwyer, P. J. (2003) · PubMed · Cited by 60
HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression
Chipitsyna, G. I., Słonina, D., Siddiqui, K. M., Peruzzi, F., Skórski, T., Krzysztof Reiss, F., Sawaya, B. E., Khalili, K., & Amini, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207417 · Cited by 40
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line.
Marchetti, P., Gallà, D. A. P., Russo, F., Ricevuto, E., Flati, V., Porzio, G., Ficorella, C., & Cifone, M. G. (2004) · PubMed · Cited by 31
Regulation of p53 stabilization by DNA damage and protein kinase C.
Johnson, C., Lu, D., Huang, J., & Basu, A. (2002) · PubMed · Cited by 31
Seo, Y. R., Chen, E. I.-T., & Smith, M. L. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1014913708916 · Cited by 10
Cited by
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Alcindor, T., & Beauger, N. (2011) · Current Oncology · doi:10.3747/co.v18i1.708 · Cited by 432
Liu, T., Zhang, X., Du, L., Wang, Y., Liu, X., Tian, H., Wang, L., Li, P., Zhao, Y., Duan, W., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0981-7 · Cited by 264
RetractedInhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Akins, N. S., Nielson, T. C., & Le, H. V. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180523111351 · Cited by 253
Liu, B., & Wang, H. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11321 · Cited by 56
Lu, W.-Q., Hu, Y.-Y., Lin, X.-P., & Fan, W. (2017) · Oncotarget · doi:10.18632/oncotarget.17396 · Cited by 49
“Anti-apoptosis represents another important mechanism for oxaliplatin-resistance [36].”
Background
Metadata
- Authors
- Arango, D., Wilson, A. J., Shi, Q., Corner, G. A., Arañes, M. J., Nicholas, C., Lesser, M., Mariadason, J. M., & Augenlicht, L. H.
- Venue
- British Journal of Cancer
- Published
- 2004-11
- Volume
- 91
- Issue
- 11
- Pages
- 1931-1946
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2146356730
- Cited by
- 274
- References
- 49
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.